Table 1 Baseline characteristics, investigations and primary treatment of patients with prostate cancer who developed castrate resistance
From: Estimating cost of prostate cancer management: an experience from Tanzania
Variable | Proportion, (%) |
|---|---|
Gleason score | |
7 | 95 (32.3) |
8 | 73 (25) |
9 | 122 (41.6) |
10 | 3 (1.1) |
PSA (ng/ml) | |
50–75 | 46 (15.6) |
75–100 | 104 (35.4) |
> 100 | 143 (49) |
Radiological investigations | |
Ultrasonography of AP | 62 (64.6) |
Lumbar-sacral X-ray | 49 (51) |
Chest X-ray | 32 (33.3) |
MR imaging of spine | 13 (13.5) |
Treatment modality | |
Bilateral subcapsular orchiectomy | 53 (55.2) |
Medical androgen deprivation | 17 (17.7) |
Both | 26 (27.1) |